September 29th 2023
Learn more about the in-depth topics covered in the September 2023 Frontline Forum BCC management supplement of Dermatology Times.
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Expert Illustrations and Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
Register Now!
Best Practice in the Multidisciplinary Care of the Patient with HS
View More
Addressing Challenges in the Management of HS in Special Populations
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Cases and Conversations™: Enhancing Diagnosis and Evaluation of Generalized Pustular Psoriasis in Advanced Practice Settings
View More
Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
View More
Clinical ShowCase™ in Atopic Dermatitis: Personalized Management Plans for Pediatric Patients
View More
20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Facing the Changing Landscape for Neuromodulators and Dermal Fillers
View More
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Advances In™: Aligning Pathology and Oncology Efforts in the Community to Improve NSCLC Care
View More
FDA Approves Relatlimab Plus Nivolumab for Unresectable or Metastatic Melanoma
March 18th 2022The FDA has approved the fixed-dose combination of relatlimab plus nivolumab for the treatment of adult and pediatric patients who are 12 years of age or older and who have unresectable or metastatic melanoma.
Pembrolizumab Demonstrates Improvement in IIB, IIC Melanoma
March 7th 2022Merck announced that pembrolizumab led to significant improvement in distant metastasis-free survival (DMFS) compared to placebo as adjuvant therapy for patients with resected stage IIB and IIC melanoma in the phase 3 KEYNOTE-716 trial.
FDA Accepts IND for RM-1995 Photoimmunotherapy in Advanced Cutaneous or Head and Neck SCC
January 6th 2022The FDA has accepted an investigational new drug application for the photoimmunotherapy treatment, RM-1995, for patients with advanced cutaneous squamous cell carcinoma or head and neck squamous cell carcinoma.
Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA
October 14th 2021The European Medicines Agency has validated its marketing authorization application for the fixed-dose combination of relatlimab and nivolumab in the frontline treatment of adult and pediatric patients with advanced melanoma.